Biosimilar infliximab: similar efficacy and safety after switching

June 10, 2015 6:59 AM

The comparable safety and efficacy of switching patients to a biosimilar anti-TNF-alfa monoclonal antibody from the reference medicinal product has been further established in data presented at EULAR 2015.

Data from abstracts published or presented at the conference (the annual meeting of the European League Against Rheumatism) show that the effectiveness of biosimilar infliximab CT-P13, developed and manufactured by Celltrion, Inc., was similar to the reference medicinal product (RMP) in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients who were switched from the RMP to the biosimilar infliximab, with no additional safety signals.

Similar immunogenicity between biosimilar infliximab and the RMP in patients with RA and AS was also demonstrated in another study presented at EULAR 2015. Professor Jürgen Braun, Professor of Rheumatology at the Free University Berlin and the Ruhr University Bochum, Germany, and lead author of the immunogenicity study, concluded that “no immunogenic difference between biosimilar infliximab and the RMP was found in two studies of patients with RA or AS.”

In the study by Sokka et al,1 39 RA and AS patients were switched from the RMP to biosimilar infliximab after a mean (SD) of 4.1 (2.3) years of treatment with the RMP. After a median of 11 (7.5 – 13) months following the first administration of biosimilar infliximab, patients’ symptom levels (pain, fatigue, patient global health) and disease activity (doctor global assessment of activity, Health Assessment Questionnaire, and erythrocyte sedimentation rate and C-reactive protein levels) were clinically assessed. The effectiveness of biosimilar infliximab appeared similar to the RMP in patients who switched from the RMP to biosimilar infliximab and no immediate safety signals were observed.

Intrinsic and extrinsic factors affecting anti-drug antibody (ADA) development 
A retrospective analysis for factors related to immunogenicity was performed using data from the PLANETRA and PLANETAS studies, which have previously demonstrated the biosimilarity of CT-P13 to its RMP. Data from the 852 patients (602 RA and 250 AS patients) in the studies showed similar immunogenicity results during the study period in both trials. The only statistically significant influencing factor was age in the PLANETRA study. Concomitant medication (methotrexate/glucocorticoid) did not appear to have an impact on ADA formation.

Dr Stanley Hong, President and CEO of Celltrion Healthcare, said: “Once again we see clinical evidence demonstrating the safety and efficacy of biosimilar infliximab and supporting the switchability of the treatment. A cost-effective treatment option like biosimilar infliximab will help to decrease the current and extensive burden on healthcare systems across Europe. These financial pressures can lead to rationing of biologic medicines like anti-TNFs for the treatment of devastating conditions like rheumatoid arthritis and ankylosing spondylitis. We are proud that biosimilar infliximab is available for patients across the European Union, offering them a more accessible treatment option to manage their disease.”

A meta-analysis of the safety data for biosimilar infliximab and its RMP showing that the safety profiles of both drugs in patients with RA and AS are consistent has also been reported at EULAR 2015.

Source: Celltrion Healthcare press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!